Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Unknown 3Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 5Polycystic Ovary Syndrome 4Pancreatic Neoplasms 2Neoplasm Metastasis 2Insulin Resistance 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Myeloid 1Racism 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Leukemia, Myeloid, Acute 1Infertility 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectum 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Brain Neoplasms 1Anovulation 1

Interventions

pembrolizumab 3NVP-BKM120 2Bevacizumab 2trastuzumab duocarmazine 1talazoparib 1sitravatinib 1ponatinib 1niraparib 1mirvetuximab soravtansine 1lenvatinib 1dostarlimab 1dactolisib 1bemarituzumab 1Trastuzumab 1Taxes 1TAS-116 1Sevoflurane 1Radiotherapy 1Propofol 1Proflavine 1Polymerase Chain Reaction 1Paclitaxel 1PM 01183 1Methods 1Metformin 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Letrozole 1Interviews as Topic 1Gene Expression Profiling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Endometrial Neoplasms × Metformin × Clear all
NCT02042495 2016-08-30

Endometrial Cancer Biomarker Changes Following Exposure to Metformin

Jewish General Hospital

Phase 2 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡